NuPathe Inc. Named Emerging Life Sciences Company of the Year

CONSHOHOCKEN, PA--(Marketwire - May 06, 2011) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announced that it received the Emerging Life Sciences Company of the Year Award at Wednesday night’s Enterprise Awards hosted by the Greater Philadelphia Alliance for Capital and Technologies (PACT).

The Enterprise Awards is considered the most prestigious Life Sciences and Technology Awards program in the Greater Philadelphia region. NuPathe was selected Emerging Life Sciences Company of the Year by a panel of leading Life Sciences CEOs, entrepreneurs, professionals, and investment bankers. Amongst the reasons cited for the award include NuPathe’s successful initial public offering of common stock in August 2010 in an extremely difficult financing environment and FDA’s acceptance for filing of the company’s NDA for its lead product candidate, a single-use transdermal sumatriptan patch for migraine.

“The Greater Philadelphia region boasts a wealth of outstanding life sciences companies, and being honored in this elite group is a testament to our business strategy and the amazing efforts of the NuPathe team,” said Jane Hollingsworth, chief executive officer of NuPathe. “As we prepare to commercialize our migraine patch, we are thrilled to be in a position to draw on the rich talent available in the region to deliver on our promise to address significant unmet patient needs in the neurosciences.”

About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe’s lead product candidate, Zelrix, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson’s disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.